Neurol. pro Praxi, 2004; 4: 218-221

SPECT v diagnostice parkinsonových syndromů

prof. Dr. Univ. Walter Pirker
Neurologische Abteilung der Krankenanstalt Rudolfstiftung, Wien

Keywords: SPECT, Parkinsonova nemoc, dopamin, bazální ganglia.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pirker UW. SPECT v diagnostice parkinsonových syndromů. Neurol. praxi. 2004;7(4):218-221.

Diferenciální diagnostika parkinsonových syndromů má z terapeutických a prognostických důvodů velký význam. Postmortální vyšetření ukázala, že spolehlivost pro klinické diagnózy Parkinsonovy nemoci samotné ve specializovaných centrech a při dodržování striktních kritérií je maximálně 90 %. Esenciální tremor a jiné tremorové syndromy, medikamentózně indukovaný parkinsonský syndrom, vaskulární parkinsonský syndrom, parkinsonské syndromy v rámci onemocnění demencí a atypická parkinsonská onemocnění degenerativní etiologie jako multisystémová atrofie nejsou hojně správně diagnostikovány. Vyšetření SPECT s dopamintransportujícími ligandy jako [123I]beta-CIT dovolují již v časném stadiu spolehlivou dokumentaci dopaminergní degenerace u idiopatické Parkinsonovy nemoci (PN) a u atypických parkinsonských onemocnění, a tím dostatečné odlišení od nedegenerativních parkinsonských syndromů s třesem. Dopamin transporterová SPECT vyšetření umožňují kromě toho diferencování demence s Lewyho tělísky od Alzheimerovy demence. SPECT vyšetření postsynaptických D2 receptorů s [123I]IBMZ může být přínosné k diferenciální diagnóze mezi idiopatickou Parkinsonovou nemoci a multisystémovou atrofií ev. progresivní supranukleární paralýzou.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body parkinson's disease. Neurology 2001; 57: 1497-1499. Go to original source... Go to PubMed...
    2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991;1 14: 23: 2283-2301. Go to original source... Go to PubMed...
    3. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555. Go to original source... Go to PubMed...
    4. Pirker W, Asenbaum S, Hauk M, et al. Imaging serotonin and dopamine transporters with iodine-123-?-CIT SPECT: Binding kinetics and effects of normal aging. J Nucl Med 2000; 41: 36-44. Go to PubMed...
    5. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272. Go to original source... Go to PubMed...
    6. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single photon emission computed tomographic [123I]?-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598. Go to original source... Go to PubMed...
    7. Asenbaum S, Brücke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-?-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38: 1-6. Go to PubMed...
    8. Brücke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I]?-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm [Suppl] 1997; 50: 9-24. Go to original source...
    9. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003; 18(Suppl 7): 43-51. Go to original source... Go to PubMed...
    10. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I]?-CIT-SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237. Go to original source... Go to PubMed...
    11. Pirker W, Asenbaum S, Bencsits G, et al. [123I]?-CIT SPECT in Multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration. Mov Disord 2000; 15: 1158-1167. Go to original source... Go to PubMed...
    12. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: Studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991; 11: 220-228. Go to original source... Go to PubMed...
    13. van Royen EA, Verhoeff NPLG, Speelman JD, Wolters EC, Kuiper MA, Jansen AGM. Diminished striatal dopamine D2 receptor activity in multiple system atrophy and progressive supranuclear palsy, demonstrated by 123I-IBZM SPECT. Arch Neurol 1993; 50: 513-516. Go to original source... Go to PubMed...
    14. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 1999; 53: 1020-1025. Go to original source... Go to PubMed...
    15. Antonini A, De Notaris R, Benti R, De Gaspari d, Pezzoli G. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease J Neurol Sci 2001; 22: 45-46. Go to original source... Go to PubMed...
    16. Walker Z, Costa DC, Walker RW, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134-140. Go to original source... Go to PubMed...
    17. Gerschlager W, Bencsits G, Pirker W, et al. [123I]?-SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002; 17: 518-523. Go to original source... Go to PubMed...
    18. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T. [123I]??-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105: 1213-1228. Go to original source... Go to PubMed...
    19. Marshall V, Grosset DG. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 2003; 18(Suppl 7): 22-27. Go to original source... Go to PubMed...
    20. Pirker W. Practical indications for SPECT and MR in movement disorders. Syllabus "Teaching Course Movement Disorders", 7th Congress of the European Federation of Neurological Societieties (EFNS), Helsinki 2003: 1-35. Published online: www.efns.org.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.